Gastroenterology. 1985;88(1 Pt 1):64– 69. 19. Bækdal TA, Borregaard J, Donsmark M, et al. Evaluation of the effects of water volume with dosing and post-dose fasting per- iod on pharmacokinetics of oral semaglutide. Diabetes. 2017;66 (Suppl 1):1179– P. 20. Hagymási K, Müllner K, Herszényi L, et al. Update on the pharma- cogenomics of proton pump inhibitors. Pharmacogenomics. 2011;12(6):873– 888. 21. Granhall C, Donsmark M, Golor G, et al. Safety, tolerability, and pharmacokinetics of multiple dosing of oral semaglutide in healthy males and males with T2D [abstract 1192]. Presentation at 77th American Diabetes Association Meeting;2017 June 9– 13; San Diego, CA . 876 T. A. BÆKDAL ET AL.22. Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once- weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, paral- lel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5:355– 366. 23. Kapitza C, Dahl K, Jacobsen JB, et al. Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. Diabetologia. 2017;60:1390– 1399. 24. Nauck MA, Petrie JR, Sesti G, et al. Study 1821 Investigators. A Phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with Type 2 diabetes. Diabetes Care. 2016;39(2):231– 241. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY 877